



GlaxoSmithKline Consumer Healthcare Ltd.

Patiala Road,
Nabha (Punjab)
147201

T (01765) 306400
F (01765) 220642
E contact.4.gsk@gsk.com
www.gsk.com

August 8, 2017

Corporate Relations (Listing Department)
The Bombay Stock Exchange Ltd.
Stock Exchange Towers
Dalal Street, Fort
Mumbai - 400 023

Manager - Listing Department
National Stock Exchange of India Ltd.
C – 1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra (East)
Mumbai - 400 05

Dear Sirs,

Sub: Un-audited Financial Results for quarter ended June 30, 2017

We would like to inform you that the Board of Directors at a meeting held on Tuesday, August 8, 2017 at 05:00 p.m. at Factory Conference Room, GlaxoSmithKline Consumer Healthcare Limited, Patiala Road, Nabha 147201 (Punjab) have, inter alia, considered and taken on record the Unaudited Financial Results for the quarter ended June 30, 2017. We are enclosing a copy of the Unaudited Financial Results for the quarter ended June 30, 2017 along with the "Limited Review" Certificate, issued by the Auditors for the review done by them, for your records.

The above may please be taken as our intimation under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited

Shanu Saksena
Company Secretary
M.No: ACS-13405

Encl: as above

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Pallala Road, Nabha - 147 201 (Punjab)

Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.

Tel. No. 01765-306400; Fax No. 01765-220642

CIN: L24231PB1958PLC002287

Email ID: investor-2@gsk.com

Website: www.gsk-ch.in



Statement of Standalone Unaudited Results for the Quarter ended June 30, 2017						(Rs. in Lakhs)
PARTICULARS						
(Refer Notes Below)						
	3 Months Ended 30/06/2017	UNAUDITED	Preceding 3 Months Ended 31/03/2017	Corresponding 3 Months Ended 30/06/2016 in the previous year	UNAUDITED	Year to date figures for the previous year ended 31/03/2017
1	Income					
	(a) Revenue from Operations	10,45,88	12,08,76	10,59,38	44,21,09	
	(b) Other Income	55,69	70,96	59,18	2,43,88	
	Total Income	11,01,57	12,79,72	11,18,56	46,64,97	
2	Expenses					
	(a) Cost of materials consumed	3,16,76	2,99,72	2,88,97	11,50,75	
	(b) Purchase of stock-in-trade	29,89	47,19	24,95	1,53,85	
	(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	(4,04)	29,82	(37,67)	(7,66)	
	(d) Excise duty	60,54	1,06,89	1,15,48	4,34,63	
	(e) Employee benefits expense	1,33,75	1,03,62	1,26,21	4,58,03	
	(g) Depreciation and amortisation expense	17,01	17,70	14,67	64,18	
	(g) Other expenses					
	(i) Advertising & promotion					
	(ii) Others	1,27,84	1,79,52	1,21,55	5,14,67	
	(h) Finance costs	2,14,79	2,31,23	2,16,37	8,83,33	
	Total Expenses	8,97,08	10,10,26	8,71,17	36,54,56	
3	Profit before exceptional Items and taxes (1-2)	2,04,49	2,69,46	2,47,39	10,10,41	
4	Exceptional Items					
5	Profit before tax (3 + / - 4)	2,04,49	2,69,46	2,47,39	10,10,41	
6	Income Tax expense					
	(a) Current Tax	69,87	99,10	89,11	3,70,24	
	(b) Deferred Tax	2,39	(5,52)	(2,33)	(16,50)	
7	Total Tax expense	72,26	93,58	86,78	3,53,74	
8	Profit for the period (5 + / - 6)	1,32,23	1,75,88	1,60,61	6,56,67	
A	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
	Remeasurements of post-employment benefit obligations					
	(ii) Income tax relating to items that will not be reclassified to profit or loss					
B	Income tax relating to items that will be reclassified to profit or loss					
	(i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
	Total other comprehensive income, net of income tax					
9	Total comprehensive income for the period (7 + / - 8)	1,32,23	1,78,61	1,59,19	6,78,27	
10	Paid Up equity share capital (Face Value of Equity Shares)	42,06	42,06	42,06	42,06	
11	Earnings per share (of Rs 10/- each) (not annualised):					
	(a) Basic	31,44	41,82	38,19	156,15	
	(b) Diluted	31,44	41,82	38,19	156,15	

Notes to the financial results:

- This statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 8, 2017. The statutory auditors have carried out limited review of the standalone results for the quarter ended June 30, 2017.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IndAS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- Basis management assessment, the Company has only one reportable segment which is Nutrition. Accordingly no separate disclosure of segment information have been made.
- The figures for the quarter ended March 31, 2017 are the balancing figures between the audited financial results for the year ended March 31, 2017 and the published unaudited results for the nine months ended December 31, 2016.
- Figures for the previous period have been regrouped wherever necessary, to conform to the current period's classification.

Place: Nabha
Date : August 8, 2017

ON BEHALF OF THE BOARD

Manoj Kumar
Manoj Kumar
Managing Director
DIN: 07177262



Price Waterhouse


Chartered Accountants

The Board of Directors
GlaxoSmithKline Consumer Healthcare Limited
24-25 Floor, One Horizon Centre,
Golf Course Road,
Sector 43, DLF Phase V
Gurgaon 122002, Haryana, India

1. We have reviewed the unaudited financial results of GlaxoSmithKline Consumer Healthcare Limited (the "Company") for the quarter ended June 30, 2017 which are included in the accompanying 'Statement of Standalone Unaudited results for the quarter ended June 30, 2017' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Nabha
Date: August 08, 2017

For Price Waterhouse
Firm Registration Number: 301112E
Chartered Accountants



Pramit Agrawal
Partner
Membership Number: 099903